Spero Therapeutics

Spero Therapeutics and GSK Secure FDA Approval for Oral cUTI Treatment Utebzi After Four-Year Regulatory Journey

Spero Therapeutics and GSK have secured FDA approval for Utebzi, an oral treatment for complicated urinary tract infections (cUTI), four years after an initial rejection. This milestone validates Spero's R&D, leverages GSK's commercial prowess, and offers a new therapeutic option for a challenging infectious disease, impacting procurement, regulatory, and business development strategies.